About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

NCT00219323·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis

With

Daiichi Sankyo Co., Ltd.

Age

20–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Allergic asthma patients
Inadequately controlled patients

You may not be if

\- History of severe anaphylactoid or anaphylactic reactions
Previous treatment with omalizumab
History of cancer or cancer

The record

StatusCompleted

PhasePhase 3

Taking part133

StartedNov 2003

UpdatedOct 25, 2011

Conditions

Where1

This study is not being conducted in the United States
Tokyo, Japan